Financial Results, New Products, and Stock Price Movements - Research Report on Hologic, Johnson & Johnson, Boston Scientific, Elan, and Amedisys

NEW YORK, November 15, 2013 /PRNewswire/ --

Today, Analysts' Corner announced new research reports highlighting Hologic, Inc. (NASDAQ: HOLX), Johnson & Johnson (NYSE: JNJ), Boston Scientific Corporation (NYSE: BSX), Elan Corporation, plc (ADR) (NYSE: ELN), and Amedisys Inc. (NASDAQ: AMED). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.

Hologic, Inc. Research Report

On November 11, 2013, Hologic, Inc. (Hologic) announced its Q4 FY 2013 financial results (period ended September 28, 2013). The Company's total revenues increased 5.7% YoY to $622.1 million during the quarter. Net loss was $1.1 billion or $4.11 per diluted share in Q4 FY 2013, compared to net loss of $77.8 million or $0.29 per diluted share in Q4 FY 2012. Commenting on the results, Jack Cumming, President and CEO, said, "We have made significant progress in recent months in reviewing the strategy, leadership and cost structure of each of our businesses, all with a focus on making changes to the organization that will enable us to leverage our strong product platforms going forward. We expect fiscal 2014 to be a transitional year for the Company and we remain confident the changes we are making to enhance the organization, combined with improving trends across our portfolio of market-leading products, will drive stronger financial performance in fiscal 2015 and beyond." The Full Research Report on Hologic, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/d132_HOLX

--

Johnson & Johnson Research Report

On November 11, 2013, Ethicon Endo-Surgery, Inc. (Ethicon), part of the Johnson & Johnson Family of Companies (Johnson & Johnson), reported that its first-to-market ENSEAL G2 Articulating Tissue Sealer is now available nationwide. According to the Company, ENSEAL G2 Articulating is the only articulating advanced energy device designed to allow surgeons to take a perpendicular approach to cut and seal vessels up to seven millimeters in diameter and lymphatics through a five millimeter port. The Company added that the ENSEAL G2 Articulating can also bend, making it easier for surgeons to access difficult to reach parts of the anatomy, and provides better access to tissue in deep or tight spaces for greater control of the angle of approach to vessels. The Full Research Report on Johnson & Johnson - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/07a8_JNJ

--

Boston Scientific Corporation Research Report

On November 12, 2013, Boston Scientific Corporation's (Boston Scientific) stock declined 1.16%, ending the day at $11.91. Over the previous three trading sessions, shares of Boston Scientific gained 2.32%, compared to the S&P 500 which gained 1.18% during the same period. The Full Research Report on Boston Scientific Corporation - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/5640_BSX

--

Elan Corporation, plc (ADR) Research Report

On November 12, 2013, Elan Corporation plc's (ADR) (Elan) stock rose 0.23%, ending the day at $17.59. Over the previous three trading sessions, shares of Elan gained 2.33%, outperforming the S&P 500 which gained 1.18% during the same period. The Full Research Report on Elan Corporation, plc (ADR) - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/e996_ELN

--

Amedisys Inc. Research Report

On November 12, 2013, Amedisys Inc. (Amedisys) reported its Q3 2013 financial results. The Company's net service revenue declined 17.2% YoY to $301.6 million during the quarter. Net loss attributable to Amedisys was $91.1 million or $2.89 per diluted share in Q3 2013, compared to net income attributable to Amedisys of $9.9 million or $0.33 per diluted share in Q3 2012. Amedisys informed that during the Q3 2013, the Company recorded an accrual of $150 million related to the tentative settlement of both the U.S. Department of Justice investigation and the Stark Law Self-Referral matter. For full-year 2013, the Company expects net service revenue to be in the range of $1.24 billion to $1.25 billion and diluted EPS to be in the range of $0.20 to $0.25 based on an estimated 31.7 million shares outstanding. The Full Research Report on Amedisys Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/56b5_AMED

----

EDITOR NOTES:

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
2. Information in this release is fact checked and produced on a best efforts basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at [email protected].
5. For any urgent concerns or inquiries, please contact us at [email protected].
6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to [email protected] for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Ananya Ghosh, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

AnalystsCorner.com

SOURCE Analysts' Corner